---
document_datetime: 2024-06-06 09:14:35
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/myocet-liposomal-previously-myocet-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: myocet-liposomal-previously-myocet-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.1188493
conversion_datetime: 2025-12-25 10:36:55.590034
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Myocet liposomal

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                |
|----------------------|-----------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| T/0073               | Transfer of Marketing Authorisation                       | 22/04/2024                          | 29/05/2024                                  | SmPC, Labelling and PL           |                                                                                                                        |
| PSUSA/1172/ 202211   | Periodic Safety Update EU Single assessment - doxorubicin | 22/06/2023                          | 22/06/2023                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             | PSUSA/1172/202211.                                                                                                                                                                                                                                                                                                                         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0070   | Update of section 4.6 of the SmPC, upon request by PRAC following the assessment of EMEA/H/C/PSUSA/00001172/202111, to align the wording with the published CHMP SWP advice on the duration of contraception in female patients after cessation of treatment with genotoxic drug. The Package Leaflet has been updated accordingly. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH | 15/12/2022 | 25/01/2024 | SmPC and PL | SmPC new text Update of section 4.6 of the SmPC with a recommended duration of the contraception period for women of child- bearing potential following end of treatment of 6.5 months and to include a recommendation to seek advice for genetic counselling and fertility preservation. The Package Leaflet (PL) is updated accordingly. |
| IG/1561   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                           | 18/11/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                            |
| IB/0069/G | This was an application for a group of variations. B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                    | 22/09/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                            |
| IB/0068/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 22/07/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                    | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   |            |            |                                  |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| PSUSA/1172/ 202111 | Periodic Safety Update EU Single assessment - doxorubicin                                                                                                                                                                                                                                                                                                    | 07/07/2022 | n/a        |                                  | PRAC Recommendation - maintenance |
| II/0066            | B.II.a.3.b.2 - Changes in the composition (excipients) of the finished product - Other excipients - Qualitative or quantitative changes in one or more excipients that may have a significant impact on the safety, quality or efficacy of the product                                                                                                       | 25/11/2021 | n/a        |                                  |                                   |
| IA/0065            | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                  | 19/03/2021 | n/a        |                                  |                                   |
| IA/0064            | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                  | 18/09/2020 | n/a        |                                  |                                   |
| IB/0063            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                               | 26/08/2020 | 19/10/2020 | SmPC, Annex II, Labelling and PL |                                   |
| IA/0062/G          | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                           | 10/07/2020 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|                    | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer   |            |            |                        |                                                                                                                                           |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0061            | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                 | 13/05/2020 | n/a        |                        |                                                                                                                                           |
| IAIN/0060          | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                                                                                             | 24/10/2019 | 19/10/2020 | SmPC, Labelling and PL |                                                                                                                                           |
| PSUSA/1172/ 201811 | Periodic Safety Update EU Single assessment - doxorubicin                                                                                                                                                                                                                                                                   | 25/07/2019 | 25/07/2019 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1172/201811. |
| IB/0058            | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                | 23/10/2018 | n/a        |                        |                                                                                                                                           |
| IA/0057/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                              | 20/07/2018 | 18/07/2019 | Annex II and PL        |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| PSUSA/1172/ 201511   | Periodic Safety Update EU Single assessment - doxorubicin                                                                 | 07/07/2016   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                      |
|----------------------|---------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| IAIN/0056            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                        | 14/06/2016   | n/a        |                                  |                                                                                                                        |
| T/0054               | Transfer of Marketing Authorisation                                                                                       | 08/01/2015   | 27/01/2015 | SmPC, Labelling and PL           |                                                                                                                        |
| IA/0053              | A.7 - Administrative change - Deletion of manufacturing sites                                                             | 20/11/2014   | n/a        |                                  |                                                                                                                        |
| IB/0051              | B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products | 20/08/2014   | n/a        |                                  |                                                                                                                        |
| IA/0052              | A.7 - Administrative change - Deletion of manufacturing sites                                                             | 11/08/2014   | n/a        |                                  |                                                                                                                        |
| IAIN/0050            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                            | 06/05/2014   | 27/01/2015 | SmPC, Annex II, Labelling and PL |                                                                                                                        |
| IB/0048              | B.II.z - Quality change - Finished product - Other variation                                                              | 06/05/2014   | n/a        |                                  |                                                                                                                        |
| IA/0049              | A.7 - Administrative change - Deletion of manufacturing sites                                                             | 29/04/2014   | n/a        |                                  |                                                                                                                        |
| PSUV/0046            | Periodic Safety Update                                                                                                    | 27/06/2013   | 02/10/2013 |                                  | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                  |            |            |                                  | PSUV/0046.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------|
| IAIN/0047 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                   | 15/07/2013 | n/a        |                                  |              |
| IA/0045   | B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                                 | 08/02/2013 | n/a        |                                  |              |
| T/0044    | MA Transfer from Cephalon Europe to Teva Pharma B.V. Transfer of Marketing Authorisation                                                                                                                                                                                                                                         | 12/12/2012 | 14/01/2013 | SmPC, Labelling and PL           |              |
| IB/0043/G | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 26/07/2012 | n/a        |                                  |              |
| IB/0042   | A.2.z - Change in the (invented) name of the medicinal product - Other changes                                                                                                                                                                                                                                                   | 21/05/2012 | 29/10/2012 | SmPC, Annex II, Labelling and PL |              |
| IAIN/0041 | B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing                                                                                                                                                                                                  | 30/03/2012 | 29/10/2012 | Annex II and PL                  |              |
| IA/0040   | B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur.                                                                                                                                                                                                                        | 17/02/2012 | n/a        |                                  |              |

<div style=\"page-break-after: always\"></div>

|           | - Updated certificate from an already manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        | Monograph approved   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------|
| IB/0039/G | This was an application for a group of variations. B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product) of a specification parameter as a result of a | 16/12/2011 | n/a        |                        | safety or quality    |
| N/0038    | The MAH applied to correct some errors in section 4 of Patient Leaflet to align with section 4.8 of SmPC. Additionally, linguistic amendments were introduced in some languages following the linguistic review Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                | 30/08/2011 | n/a        | PL                     |                      |
| IB/0037   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                             | 14/07/2011 | 21/07/2011 | SmPC, Labelling and PL |                      |

<div style=\"page-break-after: always\"></div>

| IB/0036   | - Change in the batch size (including batch ranges) of the finished product - Up to 10-fold to the currently approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/06/2011   | n/a        |                        | B.II.b.4.a size compared   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|----------------------------|
| IA/0035   | B.III.1.a.3 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 08/06/2011   | n/a        |                        |                            |
| II/0031/G | This was an application for a group of variations. Update of section 4.4 of the Summary of Product Characteristics (SmPC) to include radiation recall based on post marketing and clinical data reviewed by the MAH. Section 4.4 of the SmPC has also been updated to amend the wording regarding cardiac toxicity, myelosuppression and gastrointestinal disorders as requested by the CHMP during the evaluation of the renewal procedure. In addition, the Package Leaflet has been updated to reflect the above changes and the user testing results. In addition, further to the results of the user testing, the name of an excipient is changed in the PL and Labelling and accordingly in the SmPC. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a | 17/02/2011   | 24/03/2011 | SmPC, Labelling and PL |                            |

<div style=\"page-break-after: always\"></div>

|           | or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |                              |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------|
| IA/0034   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 25/01/2011 | n/a |                              |
| IB/0033   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 09/12/2010 | n/a |                              |
| IB/0032/G | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.4.b - Change in the batch size (including batch | 17/08/2010 | n/a | size ranges) of the finished |

<div style=\"page-break-after: always\"></div>

|         | down to 10-fold B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                          |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0030  | Renewal of the marketing authorisation.                                                                                                                                                                         | 22/04/2010 | 02/07/2010 | SmPC, Annex II, Labelling and PL | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of Myocet continues to be favourable. The CHMP therefore recommended that a renewal can be granted with unlimited validity. With this procedure the MAH also updated the product information (PI). This update was made so that the PI would be in line with the current QRD requirements and the SmPC guideline. |
| II/0027 | Addition of a test to the Drug Product release specification and update of several analytical methods to be in line with Ph. Eur. methods. Opportunity is taken to submit additional supportive stability data. | 17/12/2009 | 06/01/2010 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0029 | IA_15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer                                                                                                                         | 29/11/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0028 | IA_09_Deletion of manufacturing site                                                                                                                                                                            | 15/10/2009 | n/a        | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| II/0026   | The MAH has applied to update section 4.4 of the SPC to warn practitioners to monitor the cardiac function of patients concomitantly treated with trastuzumab, as well as to update section 4.8 of the SPC to add \"cardiomyopathy\" as undesirable effect following the 10th PSUR assessment. MAH has also taken an opportunity to implement editorial changes to SPC, Annex II, Labelling and Package Leaflet. Update of Summary of Product Characteristics, Labelling and Package Leaflet   | 23/10/2008   | 24/11/2008   | SmPC, Annex II, Labelling and PL   | SPC section 4.4 was updated with the information that patients concomitantly treated with Myocet and trastuzumab must be appropriately monitored for the cardiac function due to the known increased risk of cardiotoxicity of anthracyclines when combined with trastuzumab. Furthermore, in order to clarify what types of ECG changes are more indicative of cardiac toxicity the relevant paragraph was amended with information on reduction of QRS complex. In addition, the term \"cardiomyopathy\" was added as undesirable effect in the section of Cardiac Disorders in SPC section 4.8.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0025   | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                                                                                                   | 25/09/2008   | 27/10/2008   | Annex II and PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0024   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                     | 06/06/2008   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0023   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                                                                                                                                                                                                                                                                          | 01/02/2008   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0022   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                                                                                                                                                                                                                                                                          | 03/10/2007   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| T/0021    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 07/05/2007   | 04/06/2007   | SmPC, Labelling and PL             | Transfer of the Marketing Authorisation from Zeneus Pharma Limited to Cephalon Europe.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0019   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                                                                                                                                                                                                                                                                          | 22/02/2007   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| T/0018    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 29/06/2006   | 28/07/2006   | SmPC,                              | Transfer of the Marketing Authorisation from Elan Pharma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                      |            |            | Labelling and PL                 | International Ltd to Zeneus Pharma Limited.   |
|---------|------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------|
| IB/0017 | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release | 18/04/2006 | n/a        |                                  |                                               |
| R/0014  | Renewal of the marketing authorisation.                                                              | 23/06/2005 | 15/09/2005 | SmPC, Annex II, Labelling and PL |                                               |
| IA/0016 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                  | 25/04/2005 | n/a        |                                  |                                               |
| IA/0015 | IA_09_Deletion of manufacturing site                                                                 | 25/04/2005 | n/a        |                                  |                                               |
| I/0013  | 01_Change in the name of a manufacturer of the medicinal product                                     | 23/04/2003 | 02/05/2003 |                                  |                                               |
| I/0009  | 25_Change in test procedures of the medicinal product                                                | 12/02/2003 | 26/02/2003 |                                  |                                               |
| I/0012  | 25_Change in test procedures of the medicinal product                                                | 14/01/2003 | 21/01/2003 |                                  |                                               |
| I/0011  | 25_Change in test procedures of the medicinal product                                                | 14/01/2003 | 21/01/2003 |                                  |                                               |
| I/0010  | 25_Change in test procedures of the medicinal product                                                | 08/01/2003 | 13/01/2003 |                                  |                                               |
| I/0008  | 25_Change in test procedures of the medicinal product                                                | 08/01/2003 | 13/01/2003 |                                  |                                               |

<div style=\"page-break-after: always\"></div>

| I/0007   | 01_Change following modification(s) of the manufacturing authorisation(s)                            | 25/11/2002   | 18/12/2002   | Annex II and PL        |
|----------|------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|
| I/0006   | 22_Change in shelf-life after reconstitution                                                         | 28/02/2002   | 12/04/2002   | SmPC, Labelling and PL |
| II/0005  | Quality changes                                                                                      | 20/09/2001   | 21/03/2002   | SmPC and PL            |
| I/0004   | 19_Change in specification of excipients in the medicinal product (excluding adjuvants for vaccines) | 19/09/2001   | 23/10/2001   |                        |
| T/0001   | Transfer of Marketing Authorisation                                                                  | 24/01/2001   | 21/03/2001   | SmPC, Labelling and PL |
| II/0002  | Update of Summary of Product Characteristics and Package Leaflet                                     | 16/11/2000   | 20/03/2001   | SmPC and PL            |